Effects of reactive oxygen and nitrogen species on actomyosin and their implications for muscle contractility by Tiago, Teresa et al.
Research Signpost 







Free Radicals in Biology and Medicine, 2008:   ISBN: 978-81-308-0267-1   
Editors: Carlos Gutiérrez-Merino and Christiaan Leeuwenburgh 
6 
Effects of reactive oxygen and 
nitrogen species on actomyosin 
and their implications for 
muscle contractility 
 
 Teresa Tiago1,2, Manuel Aureliano1 and Carlos Gutiérrez-Merino2 
1Centre for Marine Sciences (CCMAR) and Faculdade de Ciências e  
Tecnologia, Universidade do Algarve, Campus de Gambelas, 8005-139 Faro 
Portugal; 2Grupo de Bioenergética en Neuronas y Miocitos, Departamento  
de Bioquímica y Biología Molecular, Facultad de Ciencias, Universidad de 






     Experimental evidence accumulated during recent 
years is pointing out that numerous pathological 
conditions in skeletal and cardiac muscle are 
associated with an oxidative stress-induced muscle 
injury. Additionally, it has been postulated that 
several oxidants can directly alter contractile function 
by  oxidative  modification of  the myofibril proteins – 
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actin and myosin. Peroxynitrite (ONOO-), a potent biological oxidizing agent 
formed in the nearly instantaneous reaction of nitric oxide with superoxide 
anion, is increasingly recognized as playing a major role in the skeletal and 
cardiac muscle dysfunction. This is supported by detection of 3-nitrotyrosine, a 
protein modification produced by the reaction of peroxynitrite with tyrosine, 
on skeletal and cardiac muscle proteins during aging or in diseases associated 
with myocardial inflammation or ischemia/reperfusion insults. Although some 
studies point to a correlation of protein nitration with functional and structural 
modifications, the mechanism by which peroxynitrite may impair muscle 
contractility remains far from being elucidated. In the present review we 
address the role of reactive oxygen and nitrogen species on the structural and 
functional impairment of actomyosin ATPase activity and their implications 
for muscle contraction with particular emphasis on the oxidative modifications 
promoted by peroxynitrite on actin and myosin. 
 
1. Introduction 
Free radicals produced by pathological events or by natural consequences 
of cellular metabolism are known to damage proteins, nucleotides and lipids 
inducing cellular injury. Oxygen (ROS) and nitrogen (RNS) reactive species 
mediated protein oxidation is considered to be implicated in a broad variety of 
diseases. The cell type, the chemical characteristics of the oxidant and its site 
of generation will determine the primary cellular targets of oxidative stress. 
Studies conducted over the past decade have demonstrated the importance of 
ROS/RNS in muscle damage associated with aging and several contractile 
dysfunctions. Of particular biological relevance is peroxynitrite (ONOO-), 
whose formation is an established event in multiple insults leading to cardiac 
dysfunction resulting in selective nitration of protein tyrosine residues and 
disruption of cellular energetic control. Nevertheless, conclusive evidence 
regarding the susceptibility of muscle proteins which differ in structure, 
function and intracellular localization to the different ROS/RNS remains far 
from being elucidated.   
This review will outline our current understanding on the susceptibility of 
actomyosin filaments to oxidative stress and the functional consequences of 
eventual modifications for muscle contractility. We will focus primarily on 
peroxynitrite actions, starting by summarizing the systems involved in its 
formation and describing the multiple muscle disorders in which this potent 
oxidant has been implicated. These basic aspects of oxidative and nitrosative 
stress are followed by a discussion of the mechanisms through which 
peroxynitrite  and  other  ROS  can  impair  actomyosin  structure  and 
function.  
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2. Reactive oxygen species production in muscle 
Skeletal muscle requires very rapid and coordinate changes in energy supply 
and oxygen flux for contractile activity. Many studies have demonstrated that 
exercise is associated with an increase generation of reactive oxygen and 
nitrogen species [1,2]. It has also been postulated that during contractile activity 
the increase generation of ROS is directly related to the elevated oxygen 
consumption that occurs due to an increased mitochondrial activity. In normal 
aerobic metabolism, 2-5% of the total electron flux in mitochondria results in the 
formation of ROS [3]. ROS production by skeletal muscle plays important roles 
in signalling adaptive responses to contractile activity [4]. However, during 
aging and in some disease states these redox-regulated processes can be modified 
rendering muscle particularly vulnerable to damage.  
(a) Superoxide and nitric oxide generation in muscle. The primary ROS 
generated by skeletal and cardiac muscle are nitric oxide (NO) and superoxide 
anion (O2-) [for reviews on this topic see 4-9] (Figure 1). Superoxide anion is 
produced at a low rate in resting muscle but its production is dramatically 
enhanced during contractile activity. Besides being a by-product of 
mitochondrial electron transport, superoxide may be generated through the 
xanthine oxidase pathway, NADP(H) oxidase activity and NO synthases, 
although this latter source is poorly characterized. Superoxide anion is 
relatively innocuous in chemical terms, when compared to the highly reactive 
hydroxyl radicals. Nevertheless, superoxide radicals can give rise to other 
more reactive and damaging species, such as peroxynitrite (ONOO-) formed by 
the reaction of O2- with NO. In fact, recent evidence indicates that most of the 
cytotoxicity attributed to NO is due to peroxynitrite [10]. Nitric oxide is 
continuously generated in muscle via constitutive NO synthase isoforms, 
namely endothelial (eNOS) and neuronal (nNOS), both activated by calcium. 
NOS metabolize L-arginine and oxygen to generate NO with citrulline as a by-
product. While nNOS is strongly expressed in fast-twitch muscle fibers and 
localizes to the muscle sarcolemma, eNOS is associated with muscle 
mitochondria. This basal NO production is believed to modulate contractility 
and other intracellular processes such as mitochondrial oxygen metabolism, 
glucose homeostasis and blood flow. In heart it has been recently suggested 
that NO also regulates cardiac function through S-nitrosation of effector 
molecules such as L-type calcium channels and the sarcoplasmic reticulum 
(SR) ryanodine receptor (RyR) [11]. In contrast, high levels of NO production, 
via inducible NOS (iNOS) are associated with several contractile dysfunctions 
including inflammation/infection induced alterations in skeletal muscle 
function or cardiac dysfunctions. iNOS is not regulated by calcium, being 
limited only by substrate availability (L-arginine, which is abundant in 
muscle). As a result, iNOS produces NO at much higher rates than the two 
constitutive  isoforms.  This  contributes  to  potentiate  NO  action on  affected  
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Figure 1. Schematic diagram illustrating the different sources of superoxide anion (O2-) 
and nitric oxide (NO) in muscle cells. NO is produced endogenously via three isoforms 
of NO synthase (NOS): endothelial (eNOS) and neuronal (nNOS) constitutive isoforms 
both activated by calcium and inducible isoform (iNOS) expressed in some 
inflammatory conditions. Mitochondria generates both O2- (by-product of the electron 
transport chain) and NO (via eNOS). O2- can be also enzymatically synthesized by 
xanthine oxidase or NAD(P)H oxidase, two pathways regulated by calcium 
homeostasis. Synthesis of NO in the vicinity of O2- results in the production of 
peroxynitrite (ONOO-), a highly cytotoxic species more potent than its precursors. 
 
 
cells and can result in nitrosative stress. NO and superoxide coexist in a 
delicate balance. Slight variations in the concentration of these radicals will 
dictate whether oxidative or nitrosative pathways will be followed [12]. 
Peroxynitrite, being generated from superoxide and nitric oxide may reduce 
the effective bioavailability of both radicals [10]. This has been suggested to 
be an adaptative mechanism that potentially influences cellular responses.   
(b) Antioxidants in skeletal muscle. Muscle cells are protected from ROS-
induced damage by an array of endogenous enzymatic and non-enzymatic 
antioxidants. Three ROS-scavenging enzymes are expressed constitutively by 
skeletal or cardiac muscle: (i) superoxide dismutase (SOD) that catalyzes the 
dismutation of superoxide anion to hydrogen peroxide; (ii) catalase, in turn, 
catalyzes the conversion of hydrogen peroxide to water and molecular oxygen; 
(iii) glutathione peroxidase (GPX) also catalyses the reduction of hydrogen 
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peroxide to water using reduced glutathione (GSH) as the electron donor. 
Another endogenous defence system involves the up-regulation of stress or 
heat shock proteins (HSPs) via activation of redox-responsive transcription 
factors [13,14]. Other enzyme systems (e.g. thioredoxin) may also contribute 
to antioxidant activity although their actions in muscle have not been well 
characterized. The most important non-enzymatic antioxidant system in 
mammalian cells is GSH. In skeletal muscle, GSH ranges from 0.5 to 3 mM 
[7]. It has direct antioxidant properties (independent of GPX) and in addition 
functions to recycle other antioxidants, namely α-tocopherol and ascorbate. 
(c) ROS and muscle injury. Cellular damage arising from an imbalance 
between ROS-generating and ROS-scavenging systems has been implicated in 
a number of muscle disease states. The rise in ROS production that occurs 
during strenuous exercise has been shown to contribute to the development of 
acute muscle fatigue [1,2,7,15,16]. Conversely, oxidative stress has been 
implicated in muscle atrophy during periods of prolonged disuse [9,17]. This 
paradox can be integrated in a homeostatic model proposed by Reid [7] that 
predicts an optimal intracellular redox state for force generation in which 
deviations from this optimum, towards low or high oxidant levels, lead to loss 
of skeletal muscle force. In cardiac muscle, ROS formation has been proposed 
as a pivotal mechanism underlying contractile dysfunction occurring in 
ischemia-reperfusion insults such as heart infarct [18,19]. The ischemia-
reperfusion injury results from the reestablishment of blood flow after 
ischemia which is essential to recover tissues, but leads to a burst of reactive 
oxygen species causing an extensive damage of the tissue. Inflammatory 
processes have also been shown to increase the oxidant load to which muscles 
are exposed in different diseases, such as hyperthyroid myopathy, sepsis or 
malignant hyperthermia [20-22]. Finally, impairment of motor function is 
often associated with the specific aging-related changes in skeletal muscle, 
termed sarcopenia, which include progressive decline in skeletal muscle mass, 
ability to generate force, an enhanced susceptibility to injury and a poor ability 
to repair [23-25]. 
 
3.  Peroxynitrite and contractile dysfunction  
Studies performed in the last decade have suggested that peroxynitrite 
may be responsible, at least in part, for the skeletal or cardiac muscle 
dysfunction observed in several of the pathophysiological conditions 
mentioned above. This assumption is supported by the observed increase in 
protein 3-nitrotyrosine (3-NT), a chemically stable protein modification 
produced by the reaction of peroxynitrite with tyrosine. The accumulation of 
nitrated proteins in tissues has been widely used to define the phenotype of 
biological aging and different pathologies. It has been reported a significant 
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age-dependent accumulation of 3-NT on proteins in skeletal [25] and cardiac 
muscle [26,27]. The extent of protein-3NT has also been shown to increase in 
skeletal muscle and heart in numerous disease conditions including sepsis, 
acute lung injury, myocarditis, atrial fibrillation, doxorubicin cardiomyophathy 
or ischemia/reperfusion insults [27-29]. In addition, some reports indicated that 
administration of either superoxide scavengers or NOS inhibitors prevent the 
development of contractile dysfunction in endotoxin-induced sepsis [30-33]. 
On the other hand, direct administration of peroxynitrite or peroxynitrite-
generating compounds in muscle tissue was shown to induce a form of 
dysfunction analogous to that observed in the pathophysiological conditions 
being studied [33,34]. Moreover, peroxynitrite has been shown to be a major 
trigger of cardiac myocyte apoptosis, a crucial mode of cell death in many 
cardiac conditions, both in vitro in cultured H9C2 cardiomyocytes and in vivo 
in a rat model of myocardial ischemia-reperfusion [35]. Another study of 
Wang and collaborators [36] demonstrated that the enhancement of survival 
and prevention of apopotosis in hypoxic/reoxygenated cardiomyocytes by 
hypoxic postconditioning are associated with the reduction in peroxynitrite 
formation induced by hypoxia/reoxygenation.  
(a) Potential sites of muscle dysfunction induced by peroxynitrite. Nitric oxide 
as a neutral and small hydrophobic molecule is able to freely diffuse across 
biological membranes contrarily to superoxide, which is anionic at neutral pH. 
Therefore, peroxynitrite formation will occur predominantly close to the sites 
of superoxide generation. Peroxynitrite may be generated at the muscle cell 
surface trough the reaction of superoxide anion with nitric oxide produced by 
endothelial cells or through the infiltration of neutrophils into muscle, a 
phenomenon seen in sepsis or ischemia/reperfusion. Considering that 
peroxynitrite has a relatively long half-life when compared with other free 
radical species and is able to diffuse across biological membranes via anion 
channels (ONOO-) or passive diffusion (ONOOH) [37], intracellular 
constituents could be potential targets for peroxynitrite action. On the other 
hand, peroxynitrite is highly reactive and the reaction with cellular components 
is completed within seconds of exposure. Thus, in this particular case, 
peroxynitrite would be expected to preferentially react with outer cell 
structures altering action potential propagation and calcium homeostasis, 
thereby affecting muscle force generation and relaxation characteristics. 
Peroxynitrite may also be generated within cells, reaching especially high 
concentrations in or near mitochondria and plasma membrane as the redox 
chains of these two systems are able to produce large quantities of both 
substrates (superoxide anion and nitric oxide) needed for the formation of 
peroxynitrite. Formed in this way, peroxynitrite would have the opportunity to 
directly react with a variety of intracellular constituents. Bauer and 
collaborators [34,38-42] have originally demonstrated that the myofibrillar 
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compartment is a predominant site of peroxynitrite formation and concomitant 
protein nitration in both acute and chronic states of cardiac dysfunction. 
Among the several myofibrillar proteins showing increased tyrosine nitration, 
the most significant increases occurred in creatine kinase and myosin, two 
critical energetic controllers of cardiomyocyte contractility mediating 
production and utilization of ATP, respectively. An age-dependent 
accumulation of 3-NT was also found in sarcoplasmic reticulum Ca2+-ATPase 
(SERCA2a) skeletal and cardiac muscle isoforms with significant yields of 
nitration on individual proteins (~ 4 mol and ~3 mol of 3-NT/mol of skeletal 
and heart SERCA2a, respectively) [25,43]. Recently, proteomic analysis of 
protein nitration in skeletal and cardiac tissue of old rats identified 3-NT 
containing sequences of different cytoskeletal proteins including the myosin 
heavy chain, tropomyosin, nebulin-related anchoring protein, actinin and actin 
[26,27]. This selectivity of protein nitration in skeletal muscle may be caused 
by the combination of different factors, such as (i) protein environment during 
oxidative stress; (ii) the microenvironment and the number of Tyr residues in 
the protein; (iii) the relative abundance of the protein; (iv) the proximity to the 
subcellular sites of peroxynitrite generation; and (iv) the turnover of the 
nitrated proteins.  
(b) Functional implications of protein nitration. It is well known that tyrosine 
nitration may affect protein structure and function, nevertheless the magnitude 
of such effect will depend on the extent and location of the nitrated tyrosine 
residues within the protein. The molecular basis for enzyme inactivation by 
tyrosine nitration is still not well understood. The introduction of a NO2 group 
onto a tyrosine ring may prevent the accessibility of the substrate to the active 
site, block protein phosphorylation and by introducing a negative charge (pKa 
changes from 7.5 to 10 when tyrosine becomes nitrated) interfere with 
inter/intra molecular interactions of ionic nature or induce conformational 
changes. The best described example of functional impairment by tyrosine 
nitration is the mitochondrial manganese superoxide dismutase (Mn-SOD) 
inhibition by peroxynitrite. Nitration of this enzyme, which catalyses the 
disproportion of superoxide to oxygen (O2) and hydrogen peroxide (H2O2), 
was found to disrupt the hydrogen-bonding network at the active site leading to 
an almost complete inhibition of its activity [44]. In skeletal and cardiac 
muscle tissue, SERCA has been shown to be partially inactivated by Tyr 
nitration [43,45] which was suggested be responsible, at least in part, for the 
loss of Ca2+-homeostasis generally observed in biological aging. Protein 
nitration has also been suggested to have mechanistic relevance in the 
impairment of the creatine kinase system in the hearts of doxorubicin-treated 
mice and the peroxynitrite-treated cardiac trabeculae of rats [38,42]. In 
vascular smooth muscle it was hypothesized that peroxynitrite-induced F-actin 
nitration could lead to a depolymerization of the filament with subsequent loss 
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of myogenic tone in cerebral arteries [46]. Alternatively, tyrosine nitration of 
α-actinin, a structural protein essential for maintenance of the Z-line and for 
the integrity of the sarcomeres was suggested to be tightly coupled to the 
deterioration of the myofibrillar cross-striation pattern and consequently to the 
reduction of isometric force production in permeabilized human ventricular 
myocytes exposed to peroxynitrite [29]. Although several studies point to a 
correlation of protein nitration with functional and structural modifications, the 
molecular mechanisms by which nitrated proteins impair muscle contractility 
remains far from being elucidated. 
 
4. ROS-induced muscle injury and actomyosin 
functional impairment  
It is now relatively well established the various pathological conditions in 
skeletal muscle associated with an oxidative stress-induced muscle injury. 
Nevertheless, fundamental questions remain to be answered. What are the 
primary molecular targets that respond to changes in the redox state of skeletal 
muscle? What are the molecular mechanisms underlying the oxidative-induced 
muscle dysfunctions? The primary molecular targets can diverge depending on 
the nature of the oxidant, its site of generation (intra- or extra-cellular) and the 
proximity of the oxidant to a specific cellular component. Therefore, the 
contractile changes mediated by ROS/RNS are likely to involve more than one 
molecular target. Proteins related to calcium regulation, such as the ryanodine-
sensitive calcium release channel or the sarcoplasmic reticulum calcium-
dependent ATPase (SERCA), are prime candidates. Other potential targets are 
proteins involved in the control and utilization of energy substrates, such as 
creatine kinase. ROS/RNS may also act on regulatory proteins indirectly via 
redox-sensitive second messenger systems such as the cyclic guanosine 
monophosphate (cGMP). A growing body of evidence is also pointing out to 
the high sensitivity of the contractile filaments to oxidative stress.  
The cellular redox balance appears to have an important influence on force 
production in skeletal muscle fibres. Among all the cellular elements of the 
contractile machinery, myofibrillar Ca2+ sensitivity and the cross-bridge 
kinetics were shown to be especially susceptible to changes in the oxidation-
reduction balance within myocytes, while the SR functions (Ca2+ leak and 
uptake) are less sensitive [47,48]. In fact, several studies associate the age-
related decrease in force generation of muscle fibres and of myofibrils with 
changes in the interaction between myosin and actin during the actomyosin 
ATPase cycle [24,49,50]. More recently, it has been demonstrated that the 
decrease in force production in hyperthyroid rat soleus muscle is associated 
with failure in myofibrillar protein function due to oxidative modifications of 
the myosin heavy chain [51]. A high sensitivity of muscle myofibrils to free-
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radical-mediated oxidative stress had been noticed earlier by Nagasawa et al 
[52], who showed that skeletal muscle actin and myosin become oxidized in 
vivo following Fe-nitilotriacetate treatment in rats, an experimental model for 
iron overloaded. Furthermore, in cardiac muscle, the reversible failure of 
contraction occurring on post-ischemic reperfusion has been proposed to 
depend on covalent changes of myofibrillar proteins [53]. 
(a) Myosin sensitivity to oxidative stress. Force production in muscle is 
generated by the myosin cross-bridges which interact with actin filaments and 
allows for the sliding of the thin actin filaments over the myosin thick 
filaments. This is achieved by structural alterations of the myosin head 
inducing the transition of the actomyosin complex from states of weak to 
strong interactions (Figure 2). Briefly, in the actomyosin ATPase cycle, ATP 
binding starts to reduce the affinity of myosin for actin, and the subsequent 
hydrolysis of ATP results in a ternary complex between myosin, ADP and Pi, 
which can be blocked by γ-phosphate analogues such as vanadate (VO4-). The 
M-ADP-Pi is in rapid equilibrium with the AM-ADP-Pi complex but this is a 
low affinity interaction. This step is followed by a slow transition to a high-
affinity state of the actomyosin complex. Release of the hydrolysis products is 
then catalyzed by the rebinding of myosin to actin giving rise to about 10-nm 
displacement of the actin filament relative to the myosin filament [54]. On the 
basis of this model, it has been suggested that the age-related decrease in 
Vmax could be accompanied by alterations in the structural states of myosin 
affecting the transition from weak to strong interactions. Specifically, it was 
proposed that the changes in force production during aging result in an 
accumulation of the weak binding complexes slowing down the actomyosin 
ATPase cycle [24,55]. On the other hand, in muscle fibres, free radicals were 
shown to induce a process that enhanced the dissociation of ADP and vanadate 
from the myosin heads, and forced the transition of cross-bridges from weakly 
binding state into rigor [56]. These results are consistent with in vitro studies 
performed in our lab with purified rabbit skeletal myosin showing that 
peroxynitrite impairs the ability of vanadate to induce the intermediate 
catalytic transition state M-ADP-Pi [57]. The decrease of conformational 
flexibility of the myosin catalytic domain was than suggested to cause 
inhibition of the F-actin-activated myosin ATPase activity observed upon 
exposure of myosin to SIN-1 producing peroxynitrite fluxes close to 1 
µM/min.  
(b) Actin sensitivity to oxidative stress. Most investigations elucidating the 
mechanisms of the oxidative-induced degeneration of muscle have normally 
focused on myosin, but there are evidences that oxidative modifications of 
actin may also affect actomyosin ATPase activity and contractility. An 
example of that is the carbonyl groups and oxidation of cysteine residues found 
in actin from isolated rat hearts subjected to ischemia/reperfusion [58,59]. This  
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Figure 2. Reactive oxygen species are suggested to induce alterations of the structural 
states of myosin which lead to an impairment of the actomyosin ATP hydrolysis and 
decrease of force production. The relevant steps of the actomyosin ATP hydrolysis 
cycle are schematically represented indicating the weak and strong binding states of 
actin (A) and myosin (M). Adapted from Rayment et al [54]. 
 
has been confirmed by a study demonstrating post-ischemic oxidation of actin 
in the myocardium [60]. The novel physiological relevance of actin 
polymerization regulated by S-glutathionylation (reversible formation of 
disulphides of cysteinyl residues on proteins with gluthathione) under 
conditions of oxidative stress is also an evidence for the high sensitivity of 
actin to the cellular redox balance [61]. Moreover, S-nitrosylation of actin was 
demonstrated to inhibit annealing of short actin filaments after mechanical 
fragmentation [62]. Annealing is thought to constitute an important repair 
mechanism in vivo and myosin can exert enough force to break actin filaments 
during muscle contraction [63].   
Monomeric actin, G-actin, contains very specific functional sites on its 
surface such as myosin-binding and ATPase-activating sites, as well as 
numerous other protein-binding sites. By itself G-actin does not stimulate the 
myosin ATPase activity. In the presence of suitable concentrations of bivalent 
cations, G-actin starts to form relatively unstable nuclei followed by rapid 
elongation and formation of filamentous actin (F-actin). In muscle cells, the 
polymerization process is very important to maintain the thin filaments 
required for contraction. Oxidative conditions are known to alter both the 
kinetics of actin polymerization and interaction with myosin. Slow oxidation 
of sulfhydryls has been suggested to account for increases in the shear 
elasticity and fragility of purified actin observed after aging [64]. Several 
studies have also demonstrated that modification of the highly reactive 
sulfhydryl, Cys-374 affects functional interaction with actin (both in G and F 
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forms)-binding proteins, including myosin, as well as the supramolecular 
organization of actin [65,66]. Actin modifications can also alter muscle 
function through effects on actin’s interaction with proteins other than myosin. 
For instance, oxidative modifications of actin were shown to inhibit the 
interaction with α-actinin [67,68] and it is known that the mutation-induced 
changes in α-actinin binding sites of actin is implicated in the mechanism of 
myocyte dysfunction and heart failures in dilated cardiomyopathy [69].  
Actin structural and functional impairment has been extensively 
investigated by treating purified G-actin or F-actin with different oxidizing 
agents. These studies indicated that oxidative injuries on actin are specific and 
related to the chemical characteristics of the oxidants. Some oxidants such as 
hydrogen peroxide (H2O2), tert-butyl hydroperoxide (t-BOOH), hypochlorous 
acid (HOCl) or chloramine-T (CT) were shown to affect actin dynamics by 
decreasing the maximum rate and extent of polymerization, by forcing the 
disassembly of actin filaments and by affecting the interaction with DNAse-I 
[67,70,71]. In contrast, the specific thiol oxidant diamide was found to 
decrease the extent of polymerization without influencing the polymerization 
rate, actin filaments disassembly or DNAse-I interaction [72].  
 
5. Peroxynitrite oxidative modifications of actomyosin 
Peroxynitrite anion (ONOO-) and peroxynitrous acid (ONOOH; pKa = 
6.8) can be toxic by reacting with several biological molecules including fatty 
acids, low molecular mass antioxidant molecules (glutathione, ascorbate and 
α-tocopherol) and proteins. In addition to 3-NT formation, this oxidant can 
alter the structure and function of proteins by modifying critical amino acid 
residues. It can directly produce oxidation of protein cysteines to thiyl radicals 
(RS·), disulfides (RSSR) and eventually to sulfenic (RSOH), sulfinic (RSO2) 
and sulfonic (RSO3) acids [73,74], although at physiological pH the two 
electron oxidation leads predominantly to disulfides [75]. To a lesser extent 
peroxynitrite can oxidize other amino acids including methionines and 
tryptophans [76] or amino acid side chains which can lead to the formation of 
protein carbonyls [77]. Additionally, peroxynitrite can modify proteins by 
acting through radicals generated during its spontaneous decomposition in 
biochemical buffers and biological fluids, particularly hydroxyl (HO·) and 
nitrogen dioxide (NO2·) radicals [78,79]. As ONOO- is a very short-lived 
chemical molecule at physiological pH, less than 1 s in buffer solutions at pH 7 
[75] and less than 0.1 s in the cytosol [80,81], the efficiency of the ONOO- 
treatment in a single “bolus” is much lower than that expected to be attained 
under conditions where it is slowly released, mimicking the “in vivo” situation. 
The exposure of cells, or isolated subcellular components, to slowly released 
ONOO- can be mimicked by 3-morpholinosydnonimine (SIN-1), a 
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peroxynitrite-producing agent. SIN-1 slowly decomposes in neutral and 
weakly alkaline water solutions releasing nitric oxide (NO.) and superoxide 
anion (O2.-) [82], which react each other to produce peroxynitrite with a second 
order rate constant of (4-7) ·109 M-1·s-1 close to the diffusion limit for chemical 
reactions. This reaction is three times more efficient than SOD in scavenging 
superoxide and therefore is preferred where ever both species are present [83]. 
It is important to recall that peroxynitrite “dosage” should be calculated as a 
concentration x time product. In some pathophysiological conditions such as 
during ischemia/reperfusion syndrome and inflammation, generations rates of 
0.1-1µM/min peroxynitrite have been reported to be reached in tissues [75,84], 
where the duration of the tissue insult can last from 30 min to several hours. 
(a) Modified residues on myosin. Thiol oxidation by peroxynitrite has been 
previously attributed to loss of function in a number of proteins. On the other 
hand, the decrease in the free cysteine content of myosin has been previously 
associated with age-related inhibition of the actomyosin ATPase activity. 
Skeletal muscle myosin contains 40 cysteines including two highly reactive 
cysteines, Cys-707 (SH1) and Cys-697 (SH2). These critical residues are 
located close to the nucleotide binding site and its modification has shown to 
have functional consequences to the actomyosin complex and to force 
development of muscle contraction. Oxidation of SH1 is known to inactivate 
the K+-EDTA ATPase while simultaneously activates the Ca2+-dependent 
ATPase activity. In contrast, oxidation of both reactive cysteine residues 
inhibits all the myosin ATPase activities including the physiological actin-
activated Mg2+-ATP hydrolysis activity [85]. The observed decrease of both 
physiological and non-physiological ATPase activities upon exposure of 
purified myosin to the peroxynitrite releasing agent SIN-1 indicates that both 
Cys707 and Cys697 are oxidized by this reagent [57] (Figure 3). Moreover, the 
obtained IC50 values were very close to that found for the inhibition of the 
actin-activated Mg2+-ATPase activity demonstrating a tight correlation 
between the oxidation of the highly reactive sulfhydryls and the loss of 
actomyosin ATPase activity induced by SIN-1. These observations are in 
agreement with previous studies showing that the NO donor sodium 
nitroprusside (SNP) exerts direct effects on actin-myosin cross-bridge cycling 
by modulating critical thiols on the myosin head in permeabilized fibers [86].  
In addition to Cys oxidation, peroxynitrite can also produce 3-
nitrotyrosine formation on myosin. This modification was detected in the 25 
kDa tryptic fragment of myosin subfragment-1 upon exposure of the purified 
protein to peroxynitrite [57]. This location is consistent with the four nitrated 
tyrosines recently identified in the myosin heavy chain extracted from cardiac 
muscle of aged rats [27] (indicated in Figure 3). However, the extent of this 
chemical modification was found to be very low in the purified treated myosin, 
i.e. less than 0.05 moles 3-NT/mole of myosin when 50% of the activity was 
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already lost suggesting a secondary role of nitration in the inhibition of the 
actomyosin ATPase activity [57]. The failure of bicarbonate to enhance the 
inhibition of the F-actin stimulated myosin Mg2+-ATPase activity by 
peroxynitrite was also fully consistent with this conclusion, because 
bicarbonate potentiates 3-nitrotyrosines formation by peroxynitrite via a 
radical pathway involving the tyrosyl radical formation after the attack of CO3·- 
[75,87,88]. 
Three of the major antioxidants present in muscle cells (GSH, ascorbate 
and NADH) were found to efficiently protect against myosin inhibition by the 
peroxynitrite-releasing agent SIN-1, with an IC50 /SIN-1 ratio close to 1 for all 
of them [57]. These results pointed out that in normal physiological conditions 
the sarcoplasm concentrations of these antioxidants are high enough to ensure 
proper protection against an acute and short lasting peroxynitrite insult. 
However, the increase in the 3-nitrotyrosine content of myocardial myosin 
after ischemia-reperfusion [39,42] indicates that these antioxidant defences are 
largely depleted near myofibrils during acute oxidative insults, suggesting that 
myofibrils are very close to the subcellular sites of peroxynitrite generation. 
Indeed, myosin along with creatine kinase are the proteins showing the most 
significant increase in nitrotyrosine content, in myofibrils, after 
ischemia/reperfusion episodes [39,42]. This is consistent with the high 
concentration of myosin in the sarcoplasm of muscle cells and with the fact 
that the IC50 for inhibition of F-actin stimulated S1 Mg2+-ATPase activity by 
SIN-1 and/or synthetic peroxynitrite (molar ratio SIN-1/myosin of 
approximately 5.5) [57] is close to that reported for inhibition of creatine 
kinase [41] and nearly 4-fold lower than the one reported for sarcoplasmic 
reticulum Ca2+,Mg2+-ATPase [43,45,89]. Moreover, the age-induced nitration 
of the myosin molecule either in skeletal muscle [25] or in cardiac tissue [27] 
can be related with its long half-life and reduced rate of turnover [90].   
(b) Modified residues on actin. Peroxynitrite has been shown to nitrate purified 
actin in vitro and to alter its nucleation and polymerization properties. This is 
not surprising if we consider that the actin molecule contains 16 Tyr residues 
(the richest in Tyr of all the major myofibrillar proteins) some of them located 
in key functional regions. Aslan et al [91] have identified four nitrated residues 
(Tyr53, Tyr198, Tyr240 and Tyr362) in rabbit actin treated with 0.3 mM 
peroxynitrite (indicated in Figure 3). Nitration was shown to increase the 
nucleation and elongation rate as well as to slow down the rate of subunit 
dissociation. A possible explanation was given by the authors who proposed 
stabilization of the interactions between the pointed end of G-actin and the 
barbed end of a growing actin filament. Clements et al. [92] have also found 
nitration on purified rabbit skeletal actin treated either with a bolus of 
peroxynitrite or with SIN-1. In these studies, the authors concluded that the 
effects  of  peroxynitrite  on  actin  function,  i.e., F-actin depolymerization and  
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Figure 3. Molecular model of G-actin (PDB Id: 1J6Z) on the left, and myosin 
subfragment-1 (PDB Id: 2MYS) on the right, depicting the putative residues modified 
by peroxynitrite. ATP and Ca2+ represented as yellow and orange spheres, respectively, 
are shown just to indicate the active site on the actin structure. Cyst, Met and Tyr 
residues are represented as stick-and-spheres in red, green and purple, respectively.  
 
inhibition of G-actin polymerization, were primarily a result of nitration. On 
the other hand, studies performed in our lab indicate only a marginal role of 
tyrosine nitration for the effects promoted by peroxynitrite. Experiments on 
purified protein have shown that SIN-1 affects actin dynamics by decreasing 
the rate of G-actin polymerization and by producing an extensive 
depolymerization of the actin polymers leading to a complete block of the 
myosin ATPase activity stimulation [93]. The results highlighted a major role 
for the highly reactive cysteine and for some critical methionines to the 
observed functional alterations. Actin, containing five cysteines (all existing in 
the reduced form), including the highly reactive Cys-374, is a potential target 
molecule for protein thiol oxidation. Peroxynitrite was found to oxidize nearly 
2.5 of the 5 cysteines of G-actin with an IC50 of 10 µM for the fast reacting 
thiol, i.e, a molar ratio of approximately 1 mol SIN-1 per mol of actin. After 
cysteines, methionine residues are potential sites of oxidative modification and 
it has been suggested as a major cause of the functional impairment of 
oxidized actin [71]. Furthermore, along with cysteines and tryptophan, 
methionines belongs to the amino acids that are able to react directly with 
peroxynitrite with a second-order rate constant of 102 M-1s-1 [76]. The actin 
molecule contains 16 Met residues dispersed along the molecule. A decreased 
susceptibility to limited proteolysis by α-chymotrypsin and subtilisin of SIN-1 
treated G-actin revealed that both Met-44 and Met-47 are oxidized to the 
sulfoxide derivative. While the reactive sulfhydryl Cys374 is located at the C-
terminal region which is the binding site for several actin-binding proteins 
(including myosin), Met-44 and Met-47 are located in a loop implicated in 
monomer/monomer contact (Figure 3). The modification of these critical 
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residues by peroxynitrite could, therefore, affect the functional interaction with 
myosin as well as the G-actin/F-actin equilibrium.  
(c) Structural modifications of actomyosin.  In addition to the reduction of 
biological activity, oxidative damage of proteins can produce a distortion of 
the folded native structure resulting in an enhanced susceptibility to 
proteolysis. For the peroxynitrite-induced oxidation, inhibition of the 
actomyosin ATPase activity is paralleled by a reduce stability of both proteins. 
This has been shown by the decrease of the unfolding enthalpy (∆H) and 
critical temperature (Tc) of SIN-1 treated myosin and G-actin and further 
confirmed by the increased susceptibility to tryptic digestion. It is well known 
that unfolded oxidized proteins can be rapidly degraded by the intracellular 
proteasome [94,95] and peroxynitrite has been previously shown to increase 
the degradation of several cellular proteins by the proteasome [96]. Taking into 
account the slow turnover rate of the myofibrillar proteins [90] and the high 
concentrations of myosin and actin in muscle cells, the peroxynitrite-induced 
oxidative actomyosin unfolding could account for the rapid loss of muscle 
mass that can be observed after inflammation or ischemic insults.  
 
6. Concluding remarks 
Reactive oxygen and nitrogen species are continuously generated in 
skeletal muscle cells during normal muscle contraction and relaxation cycles, 
and it is now relatively well established that derivatives of these species may 
act as physiological modulators of skeletal muscle function. However, there 
are conditions in which the delicate balance between oxidant production and 
antioxidant defence are compromised leading to the development of muscle 
diseases. The paradox in the role of oxidants as essential molecules in the 
regulation of muscle function and as toxic by-products of metabolism is 
particularly relevant for nitric oxide (NO). When produced in low 
concentrations by the constitutive isoforms of nitric oxide synthase (NOS), NO 
functions as a signalling molecule mediating regulation of contractility and 
other intracellular functions. However, when produced in high concentrations 
by inducible NOS, NO supplies highly toxic oxidants such as peroxynitrite 
(ONOO-) resulting from the combination of NO with superoxide anion (O2-). 
One of the hallmarks of peroxynitrite-induced oxidation is nitration of protein 
tyrosine residues. The increase of this post-translational modification in 
skeletal muscle has been shown to correlate with the development of various 
pathologies and also with the more complex process of biological aging. 
In recent years, there has been a significant shift away from the 
measurements of protein oxidation products to simply monitor the presence of 
oxidative stress, to a focus on identifying specific oxidized proteins in diseases 
and establish the functional consequences of protein dysfunction induced by 
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oxidative stress. In the present review we have summarized that oxidative 
modifications of actin and myosin affect actomyosin ATPase activity and actin 
polymerization state, and that these functional and structural impairments may 
lead by themselves to skeletal and cardiac muscle dysfunctions observed in 
pathological conditions associated with an enhanced cellular oxidative stress. 
Nitration of actin and myosin has been reported in aging and some cardiac 
disease states, but a correlation of protein nitration with functional and 
structural modifications is not yet well understood. This is probably related 
with the fact that the in vitro exposure of an isolated protein to peroxynitrite 
may not always be a good model to mimic protein nitration in vivo. In addition, 
the reaction of peroxynitrite with other amino acids such as cysteine or 
methionine residues is very likely to precede tyrosine nitration, therefore 
masking the structural and functional consequences of protein nitration.  
The current rapid progress in proteomic analysis allowed us to rationalize 
the phenotype of biological aging and different pathologies by identifying 
specific post-translational modifications in skeletal or cardiac muscle proteins. 
It seems to us that the great challenge now is to identify the most relevant links 
between protein oxidation, protein dysfunction and muscle diseases, as a step 
forward for the design of new protective therapies based on more rational 
molecular grounds.    
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